Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5900-5911

  Yajima, Naoki ^a   Yamanaka, Ryuya ^a   Mine, Takashi ^b   Tsuchiya, Naoto ^a   Homma, Jumpei ^a   Sano, Masakazu ^a   Kuramoto, Terukazu ^b   Obata, Yayoi ^b   Komatsu, Nobukazu ^b   Arima, Yoshimi ^b   Yamada, Akira ^b   Shigemori, Minoru ^b   Itoh, Kyogo ^b   Tanaka, Ryuichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLUCOCORTICOID; HLA A2 ANTIGEN; HLA A24 ANTIGEN; IMMUNOGLOBULIN G; PREDNISOLONE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG TOLERABILITY; EVALUATION; FEMALE; GLIOBLASTOMA; GLIOMA; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SAFETY; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 23844524128     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0559     Document Type: Article

References (42)

1. Karpeh MS, Kelsen DP. Tepper JE. Cancer of the stomach. In: Devita VT Jr, editor. Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1092-121.
2. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-8.
3. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS, HER-2, gp 100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004;64:4980-6.
4. Murayama K, Kobayashi T, Imaizumi T, et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 2000;23:511-8.
5. Tsuda N, Nonaka Y, Shichijo S, et al. UDP-Gal: β G1cNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumor antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumor, Br J Cancer 2002;87:1006-12.
6. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 2001;53:39-46.
7. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997;45:77-87.
8. Zeltzer PM, Moilanen B, Yu JS, Black KL. Immunotherapy of malignant brain tumors in children and adults. Childs Nerv Syst 1999;15:514-28.
9. Kurpad SN, Wikstrand CJ, Bigner DD. Immunobiology of malignant astrocytomas. Semin Oncol 1994;21:149-61.
10. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-9.
11. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
12. Miyagi Y, Imai N, Sasatomi T, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides. Clin Cancer Res 2001;7:3950-62.
13. Tsuda N, Mochizuki K, Harada M, et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004;27:60-72.
14. Noguchi M, Itoh K, Suekane S, et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004;60:32-45.
15. Mine T, Sato Y, Noguchi M. et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res 2004;10:929-37.
16. Shichijo S. Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-88.
17. Nakao M, Shichijo S, Imaizumi T, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000;164:2565-74.
18. Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59:4056-63.
19. Ito M, Shichijo S, Miyagi Y, et al. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes, Int J Cancer 2000;88:633-9.
20. Gomi S, Nakao M, Niiya F, et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999;163:4994-5004.
21. Tamura M, Nishizaka S, Maeda Y, et al. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res 2001;92:762-7.
22. Harashima N, Tanaka K, Sasatomi T, et al. Recognition of the Lck tyrosine kinase as a tumor antigen by T cells of metastatic cancer patients. Eur J Immunol 2001;31:323-32.
23. Imai N, Harashima N, Ito M, et al. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer 2001;94:237-42.
24. Nishizaka S, Gomi S, Harada K, Oizumi K, Itoh K, Shichijo S. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 2000;60:4830-7.
25. Kawano K, Gomi S, Tanaka K, et al. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res 2000;60:3550-8.
26. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001;61:6459-66.
27. + prostate cancer patients. Prostate 2004;60:273-81.
28. + non-small cell lung cancer patients. Eur J Cancer 2004;40:1776-86.
29. + cancer patients. BrJ Cancer 2004;90:1563-71.
30. Azuma K, Shichijo S, Shomura H, Matsueda S, Fujii T, Itoh K. Identification of HER2/neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res Treat 2004;86:19-29.
31. + cancer patients. Int J Oncol 2004;24:967-75.
32. + prostate cancer patients. Prostate 2004;60:205-13.
33. + patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004;53:479-89.
34. + prostate cancer patients. Br J Cancer 2004;91:287-96.
35. + prostate cancer patients. Prostate 2005;62:233-42.
36. Ito M, Shichijo S, Tsuda N, et al. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001;61:2038-46.
37. Komatsu N, Shichijo S, Nakagawa M, et al. New multiplexed flow cytometric assay to measure antipeptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004;64:535-45.
38. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973-9.
39. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004;22:4272-81.
40. Koga M, Komatsu N, Kawamoto N, Shichijo S, Itoh K, Yamada A, Analysis of cellular localization of SART3 tumor antigen by a newly established monoclonal antibody: heterotopic expression of SART3 on the surface of B-lineage leukemic cells. Oncol Rep 2004;11:785-9.
41. + cancer patients. Clin Cancer Res 2004;10:1112-20.
42. + colon cancer. Clin Cancer Res. In press.